[Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy]
- PMID: 16624154
[Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy]
Abstract
Objective: Gauging the acute effect of Percutaneous transluminal septal myocardial ablation (PTSMA) as a treatment for hypertrophic obstructive cardiomyopathy (HOCM).
Methods: PTSMA was performed in 52 patients with symptomatic HOCM [mean age (44.7 +/- 11.9), male 38, female 14]. All patients had echocardiography performed prior to the procedure, 3-7 days post-PTSMA.
Results: Procedure success was achieved in 41 patients, success rate was 78.8%. The average left ventricular outflow tract (LVOT) gradient was (92.64 +/- 38.69) mm Hg before the procedure, and (51.79 +/- 38.99) mm Hg after the procedure (P < 0.001). The thickness of interventricular septum (IVS) was (22.96 +/- 5.15) mm before the procedure and became (21.27 +/- 4.64) mm 3-7 days post-PTSMA (P < 0.05). The incidence of right bundle branch block development post-PTSMA was 15.38% (> 48 h), and one patient (1.92%) had complete heart block. Two patients died.
Conclusion: PTSMA is an effective non-surgical procedure for symptomatic patients with HOCM because of its low risk and its significant hemodynamic and echocardiographic improvement.
Similar articles
-
Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center.Int J Cardiol. 2004 Feb;93(2-3):197-202. doi: 10.1016/j.ijcard.2003.03.005. Int J Cardiol. 2004. PMID: 14975547
-
Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy--a meta analysis.Int J Cardiol. 2006 Sep 10;112(1):80-4. doi: 10.1016/j.ijcard.2005.10.009. Epub 2006 Feb 28. Int J Cardiol. 2006. PMID: 16507323
-
Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.Int J Cardiol. 2003 Mar;88(1):27-32. doi: 10.1016/s0167-5273(02)00381-9. Int J Cardiol. 2003. PMID: 12659981 Clinical Trial.
-
Percutaneous transluminal septal myocardial ablation: past, present, and future.J Cardiol. 2022 Sep;80(3):211-217. doi: 10.1016/j.jjcc.2021.11.023. Epub 2021 Dec 16. J Cardiol. 2022. PMID: 34924238 Review.
-
Percutaneous transluminal septal myocardial ablation.Curr Cardiol Rep. 2000 Mar;2(2):160-5. doi: 10.1007/s11886-000-0014-5. Curr Cardiol Rep. 2000. PMID: 10980888 Review.
MeSH terms
LinkOut - more resources
Full Text Sources